 |
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Previous Article | Next Article
The Journal of Neuroscience, November 1, 2002, 22(21):9612-9617
A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding
Raquel Gómez1, Miguel Navarro1, Belén Ferrer2, José M. Trigo1, Ainhoa Bilbao2, Ignacio Del Arco2, Andrea Cippitelli2, Felice Nava3, Daniele Piomelli3, and Fernando Rodríguez de Fonseca2 1 University Institute of Drug Dependencies, Department of Psychobiology, University Complutense of Madrid, Madrid 28223, Spain, 2 Fundación de Investigación Carlos Haya, Hospital Universitario Carlos Haya, Málaga 29010, Spain, and 3 Department of Pharmacology, University of California, Irvine, California 92697-4625
Recent studies suggest that the endocannabinoid system modulates feeding. Despite the existence of central mechanisms for the regulation of food intake by endocannabinoids, evidence indicates that peripheral mechanisms may also exist. To test this hypothesis, we investigated (1) the effects of feeding on intestinal anandamide accumulation; (2) the effects of central (intracerebroventricular) and peripheral (intraperitoneal) administration of the endocannabinoid agonist anandamide, the synthetic cannabinoid agonist R-(+)-(2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrol[1,2,3-de]-1,4-benzoxazin-6-yl)(1-naphthalenyl) methanone monomethanesulfonate (WIN55,212-2), and the CB1-selective antagonist N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR141716A) on food intake in rats; and (3) the effects of sensory deafferentation on the modulation of feeding by cannabinoids. Food deprivation produced a sevenfold increase in anandamide content in the small intestine but not in the brain or stomach. Refeeding normalized intestinal anandamide levels. Peripheral but not central administration of anandamide or WIN55,212-2 promoted hyperphagia in partially satiated rats. Similarly, peripheral but not central administration of SR141716A reduced food intake. Capsaicin deafferentation abolished the peripheral effects of both cannabinoid agonists and antagonists, suggesting that these agents modulate food intake by acting on CB1 receptors located on capsaicin-sensitive sensory terminals. Oleoylethanolamide, a noncannabinoid fatty ethanolamide that acts peripherally, prevented hyperphagia induced by the endogenous cannabinoid anandamide. Pretreatment with SR141716A enhanced the inhibition of feeding induced by intraperitoneal administration of oleoylethanolamide. The results reveal an unexpected role for peripheral CB1 receptors in the regulation of feeding.
Key words: anandamide; cannabinoid; capsaicin; cholecystokinin; food intake; rat; satiety; SR141716A; WIN55,212-2
Copyright © 2002 Society for Neuroscience 0270-6474/02/22219612-06$05.00/0
This article has been cited by other articles:
H. Butler and M. Korbonits
Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists
Eur. J. Endocrinol., November 1, 2009; 161(5): 655 - 662.
[Abstract] [Full Text] [PDF]
G. Paulino, C. Barbier de la Serre, T. A. Knotts, P. J. Oort, J. W. Newman, S. H. Adams, and H. E. Raybould
Increased expression of receptors for orexigenic factors in nodose ganglion of diet-induced obese rats
Am J Physiol Endocrinol Metab, April 1, 2009; 296(4): E898 - E903.
[Abstract] [Full Text] [PDF]
C. S. Elangbam
REVIEW PAPER: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns
Vet. Pathol., January 1, 2009; 46(1): 10 - 24.
[Abstract] [Full Text] [PDF]
G. Burdyga, G. de Lartigue, H. E. Raybould, R. Morris, R. Dimaline, A. Varro, D. G. Thompson, and G. J. Dockray
Cholecystokinin Regulates Expression of Y2 Receptors in Vagal Afferent Neurons Serving the Stomach
J. Neurosci., November 5, 2008; 28(45): 11583 - 11592.
[Abstract] [Full Text] [PDF]
N. V. DiPatrizio and K. J. Simansky
Activating Parabrachial Cannabinoid CB1 Receptors Selectively Stimulates Feeding of Palatable Foods in Rats
J. Neurosci., September 24, 2008; 28(39): 9702 - 9709.
[Abstract] [Full Text] [PDF]
A A Izzo and M Camilleri
Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects
Gut, August 1, 2008; 57(8): 1140 - 1155.
[Abstract] [Full Text] [PDF]
M. R. Pazos, R. M. Tolon, C. Benito, C. F. Rodriguez, J. J. Gorgojo, M. Nevado, M. Alvarez, F. Arias, F. Almodovar, M. T. P. Fernandez, et al.
Cannabinoid CB1 Receptors Are Expressed by Parietal Cells of the Human Gastric Mucosa
J. Histochem. Cytochem., May 1, 2008; 56(5): 511 - 516.
[Abstract] [Full Text] [PDF]
R. W. Nesto and K. Mackie
Endocannabinoid system and its implications for obesity and cardiometabolic risk
Eur. Heart J. Suppl., March 1, 2008; 10(suppl_B): B34 - B41.
[Abstract] [Full Text] [PDF]
A. P. Chambers, V. K. Vemuri, Y. Peng, J. T. Wood, T. Olszewska, Q. J. Pittman, A. Makriyannis, and K. A. Sharkey
A neutral CB1 receptor antagonist reduces weight gain in rat
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2007; 293(6): R2185 - R2193.
[Abstract] [Full Text] [PDF]
T. Esfandyari, M. Camilleri, I. Busciglio, D. Burton, K. Baxter, and A. R. Zinsmeister
Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study
Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G137 - G145.
[Abstract] [Full Text] [PDF]
J. Fu, G. Astarita, S. Gaetani, J. Kim, B. F. Cravatt, K. Mackie, and D. Piomelli
Food Intake Regulates Oleoylethanolamide Formation and Degradation in the Proximal Small Intestine
J. Biol. Chem., January 12, 2007; 282(2): 1518 - 1528.
[Abstract] [Full Text] [PDF]
M. Bluher, S. Engeli, N. Kloting, J. Berndt, M. Fasshauer, S. Batkai, P. Pacher, M. R. Schon, J. Jordan, and M. Stumvoll
Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity
Diabetes, November 1, 2006; 55(11): 3053 - 3060.
[Abstract] [Full Text] [PDF]
V Di Marzo and A A Izzo
Endocannabinoid overactivity and intestinal inflammation.
Gut, October 1, 2006; 55(10): 1373 - 1376.
[Abstract] [Full Text] [PDF]
P. Pacher, S. Batkai, and G. Kunos
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462.
[Abstract] [Full Text] [PDF]
G. Burdyga, A. Varro, R. Dimaline, D. G. Thompson, and G. J. Dockray
Ghrelin receptors in rat and human nodose ganglia: putative role in regulating CB-1 and MCH receptor abundance
Am J Physiol Gastrointest Liver Physiol, June 1, 2006; 290(6): G1289 - G1297.
[Abstract] [Full Text] [PDF]
U. Pagotto, G. Marsicano, D. Cota, B. Lutz, and R. Pasquali
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Endocr. Rev., February 1, 2006; 27(1): 73 - 100.
[Abstract] [Full Text] [PDF]
P. Movahed, B. A. G. Jonsson, B. Birnir, J. A. Wingstrand, T. D. Jorgensen, A. Ermund, O. Sterner, P. M. Zygmunt, and E. D. Hogestatt
Endogenous Unsaturated C18 N-Acylethanolamines Are Vanilloid Receptor (TRPV1) Agonists
J. Biol. Chem., November 18, 2005; 280(46): 38496 - 38504.
[Abstract] [Full Text] [PDF]
B. Kola, E. Hubina, S. A. Tucci, T. C. Kirkham, E. A. Garcia, S. E. Mitchell, L. M. Williams, S. A. Hawley, D. G. Hardie, A. B. Grossman, et al.
Cannabinoids and Ghrelin Have Both Central and Peripheral Metabolic and Cardiac Effects via AMP-activated Protein Kinase
J. Biol. Chem., July 1, 2005; 280(26): 25196 - 25201.
[Abstract] [Full Text] [PDF]
N. Finer and U. Pagotto
Review: The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management
The British Journal of Diabetes & Vascular Disease, May 1, 2005; 5(3): 121 - 124.
[Abstract] [PDF]
E. Fride, T. Bregman, and T. C. Kirkham
Endocannabinoids and Food Intake: Newborn Suckling and Appetite Regulation in Adulthood
Experimental Biology and Medicine, April 1, 2005; 230(4): 225 - 234.
[Abstract] [Full Text] [PDF]
D. Fegley, S. Gaetani, A. Duranti, A. Tontini, M. Mor, G. Tarzia, and D. Piomelli
Characterization of the Fatty Acid Amide Hydrolase Inhibitor Cyclohexyl Carbamic Acid 3'-Carbamoyl-biphenyl-3-yl Ester (URB597): Effects on Anandamide and Oleoylethanolamide Deactivation
J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 352 - 358.
[Abstract] [Full Text] [PDF]
K. A. Sharkey and Q. J. Pittman
Central and Peripheral Signaling Mechanisms Involved in Endocannabinoid Regulation of Feeding: A Perspective on the Munchies
Sci. Signal., March 29, 2005; 2005(277): pe15 - pe15.
[Abstract] [Full Text] [PDF]
F. RODRIGUEZ de FONSECA, I. DEL ARCO, F. J. BERMUDEZ-SILVA, A. BILBAO, A. CIPPITELLI, and M. NAVARRO
THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY
Alcohol Alcohol., January 1, 2005; 40(1): 2 - 14.
[Abstract] [Full Text] [PDF]
S. Batkai, P. Pacher, D. Osei-Hyiaman, S. Radaeva, J. Liu, J. Harvey-White, L. Offertaler, K. Mackie, M. A. Rudd, R. D. Bukoski, et al.
Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension
Circulation, October 5, 2004; 110(14): 1996 - 2002.
[Abstract] [Full Text] [PDF]
G. Burdyga, S. Lal, A. Varro, R. Dimaline, D. G. Thompson, and G. J. Dockray
Expression of Cannabinoid CB1 Receptors by Vagal Afferent Neurons Is Inhibited by Cholecystokinin
J. Neurosci., March 17, 2004; 24(11): 2708 - 2715.
[Abstract] [Full Text] [PDF]
G. P. Ahern
Activation of TRPV1 by the Satiety Factor Oleoylethanolamide
J. Biol. Chem., August 15, 2003; 278(33): 30429 - 30434.
[Abstract] [Full Text] [PDF]
|
|
|
|
 |
|